Department of Cell Cultures and Genomic Analysis, Medical University of Lodz, Zeligowskiego 7/9, 90-752 Łódź, Poland.
Int J Mol Sci. 2021 Nov 20;22(22):12530. doi: 10.3390/ijms222212530.
Forkhead box O3 (FOXO3a) is a member of a subfamily of forkhead transcription factors involved in the basic processes within a cell, including proliferation, apoptosis, cell cycle regulation, and DNA damage. As a transcription factor, FOXO3a is involved in the response to cellular stress, UV radiation, or oxidative stress. Its regulation is based on the modification of proteins as well as regulation by other proteins, e.g., growth factors. FOXO3a is commonly deregulated in cancer cells, and its inactivation is associated with initiation and progression of tumorigenesis, suggesting its role as a tumor suppressor; however, its role is still disputed and seems to be dependent on upstream signaling. Nevertheless, FOXO3a serves as an interesting potential target in therapies as it is regulated during treatment with very common anti-cancer drugs such as paclitaxel, cisplatin, docetaxel, and doxorubicin. This review aims to update the reported role of FOXO3a in prostate cancer (PCa), with a focus on its regulators that might serve as potential therapeutic agents in PCa therapy.
叉头框蛋白 O3（FOXO3a）是叉头转录因子亚家族的一员，参与细胞内的基本过程，包括增殖、凋亡、细胞周期调控和 DNA 损伤。作为转录因子，FOXO3a 参与细胞应激、紫外线辐射或氧化应激的反应。其调节基于蛋白质的修饰以及其他蛋白质（如生长因子）的调节。FOXO3a 在癌细胞中通常失调，其失活与肿瘤发生的起始和进展有关，提示其作为肿瘤抑制因子的作用；然而，其作用仍存在争议，似乎依赖于上游信号。尽管如此，FOXO3a 作为一种有趣的潜在治疗靶点，因为它在接受非常常见的抗癌药物（如紫杉醇、顺铂、多西他赛和阿霉素）治疗时受到调节。本综述旨在更新 FOXO3a 在前列腺癌（PCa）中的报道作用，重点介绍其可能作为 PCa 治疗中潜在治疗剂的调节剂。
